Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

The approval was supported by data from the registry-linked, parallel group, open-label, randomized AcT trial, which compared tenecteplase to alteplase.

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful ...

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...

The standard treatment for these strokes involves removing the clot using a thin tube (catheter) or a stent, a procedure ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful ...